An Advanced Tool To Interrogate BRD9

  • J Med Chem. 2016 May 26;59(10):4459-61. doi: 10.1021/acs.jmedchem.6b00550.
Rezaul M Karim  1  2 ,  Ernst Schönbrunn  1  2
Affiliations
  • 1. Drug Discovery Department, Moffitt Cancer Center , Tampa, Florida 33612, United States.
  • 2. Department of Molecular Medicine, University of South Florida , Tampa, Florida 33612, United States.
PMID: 27120693 DOI: 10.1021/acs.jmedchem.6b00550
Abstract

Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. A selective small molecule inhibitor that is well tolerated and has proper pharmacokinetic properties is required to explore the function of BRD9 in diseases. BI-9564 (2) is a cell permeable and noncytotoxic BRD9 Inhibitor provided to the scientific community to explore BRD9 biology and determine its potential as a drug target.

Products